Biotronik has announced the first US implantation of the Amvia Edge pacemaker. The procedure was successfully completed by Raul Weiss at Mount Sinai Medical Center in Miami, Florida.
Amvia Edge is Biotronik’s next-generation pacemaker family, featuring MRI Guard 24/7, a dedicated, always-on magnetic resonance imaging (MRI) sensor, designed to allow a clinic to automatically recognise when the patient enters an MRI field and convert the device to MRI mode. The device then automatically returns to its permanent programming following the completion of the scan.
Amvia Edge is also the first pacemaker family from Biotronik to offer EarlyCheck, another tool designed to simplify clinic workflow by automating pre-discharge checks. EarlyCheck will automatically deliver a device report and IEGM to the Biotronik Home Monitoring Service Center two hours after implant, eliminating the need for an in-person device interrogation.
“I was very pleased to have been a part of the first implant of Amvia Edge. The procedure went well, and I am excited about the benefits this new device will be able to bring to our patients as well as our practice,” said Weiss. “The ability to eliminate device scans before and after an MRI procedure is a much needed advancement, and I look forward to seeing how these types of technologies help streamline our workflows in the future.”
Additionally, Amvia Edge also offers Atrial ATP (aATP), providing multiple, automatic therapies in response to detected stable atrial arrhythmias, which may reduce atrial tachycardia burden and consequently help avoid atrial remodelling.
“I am so pleased to hear about Dr Weiss and his team’s successful first implant of Amvia Edge,” said David Hayes, chief medical Officer, Biotronik. “This new family of devices was designed to optimise workflows and therapies to benefit patients and their care teams, as well as clinicians and staff.”
